机构:[1]State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.[2]Department of Clinical Laboratory, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.[3]Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.[4]Genepioneer Biotechnologies Co. Ltd., Nanjing, Jiangsu, People's Republic of China.
Science Fund for Distinguished Young
Scholars of Xinjiang Autonomous Region,
Grant/Award Number: 2022D01E26;
Leading Talent Project of Scientific and
Technological Innovation in Tianshan
Talents Training Plan of the Xinjiang
Uygur Autonomous Region, Grant/Award
Number: 2022TSYCLJ0031; Natural
Science Foundation of Xinjiang Uygur
Autonomous Region, Grant/Award
Number: 2022D01D69; National Natural
Science Foundation of China,
Grant/Award Numbers: 82360521,
82260568; State Key Laboratory of
Pathogenesis, Prevention and Treatment
of High Incidence Diseases in Central Asia
Fund, Grant/Award Number: SKLHIDCA-2020-SG1
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
无
最新[2023]版:
大类|3 区医学
小类|3 区免疫学
第一作者:
第一作者机构:[1]State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China.[4]Genepioneer Biotechnologies Co. Ltd., Nanjing, Jiangsu, People's Republic of China.[*1]Genepioneer Biotechnologies Co. Ltd., Nanjing, Jiangsu, People’s Republic of China[*2]State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, People’s Republic of China
推荐引用方式(GB/T 7714):
Zheng Shutao,He Shuo,Liang Yan,et al.NME4 suppresses NFκB2-CCL5 axis, restricting CD8+ T cell tumour infiltration in oesophageal squamous cell carcinoma[J].Immunology.2024,doi:10.1111/imm.13838.